



EXPRESS MAIL NO: EL 477 033 814 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Richard Kroczek

Application No.: 09/823,307

Group Art Unit: 1644

Filed: April 12, 2001

Examiner: To be assigned

For: METHODS OF MODULATING T
LYMPHOCYTE COSTIMULATION

Attorney Docket No.: 7853-235-999

TECH CENTER 1600/2900

JAN 30 2002

RECEIVED

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE
AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Assistant Commissioner for Patents
Box Sequence Listing
Washington, DC 20231

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide And/Or Amino Acid Sequence Disclosures ("Notice to Comply") mailed by the U.S. Patent and Trademark Office on November 14, 2001 in connection with the above-identified application, Applicants submit herewith a second substitute Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. § 1.821 and a copy of the Notice to Comply. Also submitted herewith is a Petition for Extension of Time for the response, from January 14, 2002 up to and including February 14, 2002, together with the necessary fee.

I hereby state that the content of the paper and computer readable copies of the substitute Sequence Listing, submitted herewith in accordance with 37 C.F.R. §1.821, are the same. I hereby state that the submission herein under 37 C.F.R. §1.821(g) does not include new matter.

No fee is believed due; however, should the Patent and Trademark Office determine otherwise, please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of the sheet is attached for accounting purposes.

Respectfully submitted,

Date January 15, 2002

Laura A. Coruzzi 30,742
Laura A. Coruzzi (Reg. No.)

By: Muna Abu-Shaar

Muna Abu-Shaar
Limited Recognition Under 37 C.F.R. § 10.9(b)
Copy of Certificate Enclosed

PENNIE & EDMONDS LLP
1155 Avenue of the Americas
New York, New York 10036-2711
(212) 790-9090




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/823,307	04/02/2001	Richard KroczeK	7853-235-999

20583
PENNIE AND EDMONDS
1155 AVENUE OF THE AMERICAS
NEW YORK, NY 100362711



CONFIRMATION NO. 8614

FORMALITIES LETTER



OC000000007071867

Date Mailed: 11/14/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE